ImmuPharma plc (LON:IMM – Get Free Report)’s share price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 4.45 and traded as high as GBX 4.89. ImmuPharma shares last traded at GBX 4.30, with a volume of 1,755,733 shares changing hands.
ImmuPharma Stock Performance
The company has a 50 day moving average of GBX 4.41 and a 200 day moving average of GBX 5.70. The firm has a market cap of £24.54 million, a P/E ratio of -10.63 and a beta of 3.00.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
